RxDoctor Payments Data

Tri Trang, MD

Family Medicine · Los Angeles, CANPI 1720519267

Payments from drug & device makers

$5,599in general payments, 2019–2025

Across 237 payments — averaging $23.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Viiv Healthcare Company$3K
  • Gilead$1K
  • Amgen$507
  • Merck$271
  • Novo Nordisk$143
  • Johnson & Johnson$120
  • plus $407 from 7 others
$2,030in research payments, 2019–2025

Across 6 payments — averaging $338.41 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • GSK$1K
  • Viiv Healthcare Company$541

What the payments were for

  • Food & beverage$5,599100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,599 in reported general payments places this provider in the 90th percentile of 10,533 family medicine providers in California.

See all family medicine providers in California

Medicare billing

Part B allowed, 2024
$22,594
Medicare patients
35
Services billed
451

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BiktarvyBictegrav/Emtricit/Tenofov Ala65$272,558
DescovyEmtricitabine/Tenofov Alafenam26$64,549
TivicayDolutegravir Sodium12$29,121
IsentressRaltegravir Potassium12$21,962
TrulicityDulaglutide14$14,695
Emtricitabine-Tenofovir DisopEmtricitabine/Tenofovir (Tdf)21$828
Testosterone Cypionate21$763
Atorvastatin Calcium94$661
ValacyclovirValacyclovir Hcl19$631
Amlodipine-OlmesartanAmlodipine Bes/Olmesartan Med19$405
Metformin Hcl24$291
Famotidine19$268
Lisinopril28$160
Doxycycline Hyclate11$152
Celecoxib13$145

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GileadBiktarvy, Descovy$1,381$337,10691 claims
Viiv Healthcare CompanyTivicay$2,769$29,12112 claims
MerckIsentress$271$21,96212 claims
Lilly USA, LLCTrulicity$98$14,69514 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 10,533 family medicine providers in California.

Other family medicine in Los Angeles

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →